CAMBRIDGE, Mass.--(BUSINESS WIRE)--MoldCo is announcing the public launch of the company to address the endemic public health crisis of chronic health issues caused by mold. The company has raised $3 million in pre-seed funding with participation from Starship Ventures, SALT, Conscience VC, Boost VC, Night Ventures, Bleu Capital, Behind Genius Ventures and Moth Fund.
MoldCo was founded by CEO Ariana Thacker, a former venture capital investor and Founding Partner of Conscience VC, based on her personal experiences with serious symptoms due to mold exposure. After determining that her health challenges were caused by toxic mold, she dived deep into the research while connecting with top experts in the field. Based on this knowledge, she built MoldCo with a vision to provide evidence-based real solutions for people facing similar challenges.
“I learned first-hand the serious and neglected public health crisis caused by mold,” Thacker said. “Now with MoldCo, people have a company on their side with an evidence-based understanding of the health impacts of mold to provide treatments and care accessibly and affordably.”
MoldCo is now accepting patients in select states and will use the funding to expand nationwide in 2025. Patients can have early access by joining their waitlist on www.moldco.com.
MoldCo’s approach is guided by a patented, published and evidence-based approach that has been used to treat over 30,000 patients with Mold Illness, also known as Chronic Inflammatory Response Syndrome (CIRS). MoldCo’s customers receive access to mold-certified clinician care, specialized lab tests, and evidence-based treatments.
Multiple studies indicate over 50% of U.S. households have mold, dampness, and water damage, and the EPA claims 85% of office buildings have experienced water damage. Mainstream medicine has not traditionally recognized or addressed the pervasive and debilitating dangers of mold to people’s health, or its links to medical conditions. There is now increasing recognition of the many health issues that are caused by mold. There is also growing evidence of mold problems in large scale locations such as in military housing. MoldCo is poised to address this long-ignored area.
“Mold can cause debilitating, chronic conditions and has not been adequately addressed by traditional medical institutions. MoldCo is the first company to provide a research-backed solution to address it,” said Sean Hoge, Founder and General Partner at Starship Ventures. “Now with MoldCo, individuals facing this serious issue will no longer be alone.”
“The days of simply living with mold and biotoxin-related illness have been replaced by peer-reviewed treatment protocols, developed from nearly three decades of research and evidence-based care,” said Ritchie Shoemaker, M.D., a recognized world leader and pioneer in the treatment of mold and biotoxin-related illness, and MoldCo’s Founding Physician.
About MoldCo
MoldCo enables individuals to reclaim their health from mold. The company’s mission is to provide accessible and evidence-based care, treatments and lab testing for mold toxicity, digitally.
To learn more and join their waitlist, please visit www.moldco.com.
